Effectiveness and safety of cefpodoxime in upper respiratory tract infections in adult Egyptian population a report from the Egyptian STAR registry

Hamid, Osama; Dokhan, Mohamed Abdel Aziz Abu; Gamea, Ahmed; Ahmed, Hesham Ali; Feseekh, Nabil Taha; Deghedy, Mohamed Attwa El; Abaza, A.; Fayez, Medhat; Wahab, Mohamed Abdel; Salem, Ahmed Ali; Mahmoud, Mohsen; Nassar, Ahmed Monir; Sayed, Mohamed Ali El; Beder, Magdy; Assaly, Emad Ahmad El; Henteely, Mohamed El; Okba, Mohamed El; Hegazy, O.A.; Tabakh, Mohamed El; Seweedan, Ali; Zalat, Hussein El; Sherbiny, Yasser Ali El; Mostafa, Ezzat; Zaheer, Akram; Khalil, Osama Abdel; M, Bebawi; Ogeilee, Amir El; Naggar, Yasser El; Mahmoud, El Sayed; Farid, Essam; Farouk, Mohamed Alaa; Aouda, Essam; Khouly, Farouk Ahmed El; Makheih, Awad Ahmed El; Ashry, Mohamed Said Fathy; Yousry, Mohamed; Mohamed, Magdi Hamza; Mau, Yasser Ahmed; Nasser, M. Abd El-; Montasser, Mohamed Hussein; Hussein, Mohamed A.

doi:10.1016/j.ejenta.2017.08.002

Cited by 3 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В масштабном проспективном многоцентровом обсервационном исследовании оценивали эффективность и безопасность терапии цефподоксимом в дозе 200 мг в сутки в течение 5-10 дней (продолжительность курса лечения определялась лечащим врачом) у 1425 взрослых пациентов с острым максиллярным синуситом или острым тонзиллофарингитом [23]. Средняя продолжительность курса лечения составила 5,87 ± 1,73 дня.…”

Section: острый тонзиллофарингитunclassified

“…Эффективность терапии была достоверно выше у пациентов с острым тонзиллофарингитом в сравнении с больными острым синуситом (86,3% против 77,4% соответственно; p < 0,001). НЛР были отмечены у 0,8% пациентов, все они были легкими или умеренными по тяжести и разрешились после завершения лечения [23].…”

Section: острый тонзиллофарингитunclassified

“…Том 25 . №3 стью [15,16,23], имеет данное показание в утвержденной инструкции по медицинскому приме нению [6].…”

Section: клинические рекомендации по респираторным инфекциям и инфекц...unclassified

See 2 more Smart Citations

Oral third-generation cephalosporin cefpodoxime in the therapy of respiratory infections

Stetsiouk,

Andreeva,

Shevchik

2023

CMAC

View full text Add to dashboard Cite

Oral 3rd generation cephalosporin cefpodoxime proxetil has been available in the antibiotic armamentarium for more than 30 years, however, unlike other oral cephalosporins (e.g. cefixime), it has not been given due recognition in clinical practice in Russia due to its low availability on the domestic pharmaceutical market. At the same time, the high activity of cefpodoxime against respiratory pathogens (S. pneumoniae, H. influenzae and S. pyogenes), pharmacological characteristics, results of clinical trials of its safety and efficacy, allow us to discuss the inclusion of this antimicrobial into Russian clinical guidelines for the treatment of community-acquired respiratory infections, primarily in outpatients, as well as for stepdown therapy of these infections in the hospital. In addition, cefpodoxime is a reliable option to replace parenteral therapy, in particular with ceftriaxone, which is unreasonably often prescribed in outpatient practice in Russia, without the threat of loss of the treatment efficacy.

show abstract

Section: острый тонзиллофарингитunclassified

See 1 more Smart Citation

Oral third-generation cephalosporin cefpodoxime in the therapy of respiratory infections

Stetsiouk,

Andreeva,

Shevchik

2023

CMAC

View full text Add to dashboard Cite

show abstract

“…В связи с высокой in vitro активностью против S. pyo genes [15,17], высокими концентрациями в очаге инфекции [13,17], высокой клинической эффективностью и хорошей переносимостью [22][23][24], а также наличием соответствующего показания в утвержденной инструкции по медицинскому применению [25], цефподоксима проксетил может быть включен в КР «Острый тонзиллит и фарингит (Острый тонзиллофарингит)» [18] в качестве варианта АБТ при непереноси мости пенициллинов. Необходимо отметить, что согласно результатам международных исследований, при лечении острого стрептококкового тонзиллофарингита цефподоксимом в течение 10 и 5 дней частота микробиологической эрадикации не различалась [23,26].…”

Section: введение в проблемуunclassified

Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

Avdeev,

Andreeva,

Gorelov

et al. 2023

CMAC

View full text Add to dashboard Cite

The purpose of the expert council was to determine the place of cefpodoxime in the ABT algorithms for upper and lower respiratory tract infections and to form a consensus position on its use in clinical practice. Based on the available data, the possibility of including cefpodoxime in national guidelines for the treatment of rhinosinusitis, acute tonsillopharyngitis, community-acquired pneumonia (CAP), as well as infectious exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) is being considered.

show abstract

“…In developed countries, acute respiratory infections (ARI) account for the majority of antibiotic prescriptions and 20% of all medical consultations [10,11]. Cefpodoxime, a thirdgeneration cephalosporin, was well-suited for treating RTIs due to its broad-spectrum antibacterial properties and favorable pharmacokinetic characteristics, making it a valuable choice for empirical therapy [12,13]. Cefpodoxime, marketed as cefpodoxime proxetil, is an oral cephalosporin that exhibits superior activity against major bacterial pathogens responsible for RTIs compared to earlier generations of oral cephalosporins or amoxicillin.…”

Section: Introductionmentioning

confidence: 99%

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

2024

J. Adv. Med. Med. Res.

View full text Add to dashboard Cite

Background: Cefpodoxime's prodrug form was absorbed and de-esterified by enterocytes to release the active metabolite, and it shows good In vitro activity against bacterial pathogens causing common RTIs. It was unknown, nevertheless, how clinicians considered about cefpodoxime. Objective: To gather expert opinion on the use of cefpodoxime in the management of respiratory tract infections (RTIs) in Indian settings. Methodology: The cross-sectional survey utilized a 19-item, multiple-response questionnaire to gather expert opinions from specialists with expertise in managing RTIs. The survey encompassed questions about current prescription practices, clinical observations, preferences, and experiences related to the use of cefpodoxime in routine settings for RTI management. The data were analyzed using descriptive statistics. Results: Approximately 53% of the clinicians reported prescribing cefpodoxime in cases of upper respiratory tract infections (URTIs), while 44% of them indicated using it for lower respiratory tract infections (LRTIs). Cefpodoxime emerged as the most commonly prescribed antimicrobial agent for treating URTIs, as reported by 86% of the clinicians. Majority (86.02%) of the clinicians favored cefpodoxime as the oral drug of choice for treating acute otitis media. More than half (68.34%) of the clinicians indicated prescribing cefpodoxime for approximately 5 to 7 days in cases of URTIs. The advantages of cefpodoxime, including its broad spectrum, favorable pharmacokinetic profile, and good bacteriological and clinical efficacy, were acknowledged by 65% of clinicians. Conclusion: The survey findings corroborated cefpodoxime as a widely used antibiotic in Indian settings for managing URTIs and acute otitis media. Clinicians reported that its broad-spectrum coverage, favorable pharmacokinetic profile, and clinical efficacy contribute to its popularity in the management of RTIs.

show abstract

Effectiveness and safety of cefpodoxime in upper respiratory tract infections in adult Egyptian population a report from the Egyptian STAR registry

Cited by 3 publications

References 19 publications

Oral third-generation cephalosporin cefpodoxime in the therapy of respiratory infections

Oral third-generation cephalosporin cefpodoxime in the therapy of respiratory infections

Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

Contact Info

Product

Resources

About